Bausch, which last week adopted a poison-pill plan to prevent any unsolicited takeover bid, said Tuesday it has learned Icahn ...

(Reuters) -Billionaire Carl Icahn has a total economic exposure of about 34% to Bausch Health's common shares, the healthcare ...

Bausch Health has launched a shareholder rights plan—also known as a poison pill defense—designed to prevent any one entity ...

After enacting a “poison pill” defense to protect itself from unwanted potential buyers, Bausch Health has spotted a major ...

Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 ...

The swap agreements covering 90.7M BHC shares (24.6%) are set to mature on February 28, 2028, the company noted, adding that ...

Raymond James bullish rating for Bausch Health Companies remains unchanged after a U.S. District Court ruling.

Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Bausch + Lomb issued the recall after the company received reports of toxic anterior segment syndrome, or an inflammatory ...

Fitch Ratings upgraded its credit grade on both Bausch + Lomb Corp. and its parent company Bausch Health Cos., but said the ...

In a report released today, Michael W. Freeman from Raymond James maintained a Hold rating on Bausch Health Companies (BHC – Research Report), ...

Bausch + Lomb, a leading global eye health company, announced a voluntary recall of its Envista Aspire, Envista Envy and ...